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Clinical trials are an integral part of the proc-
ess for developing new medical innovations and
often provide unexpected information about the
safety and effectiveness of new medical products
before their approval. In December 2006, the Food
and Drug Administration (FDA) was informed by
Pfizer about suspending a large phase III trial eval-
uating the investigational cardiovascular therapy
torcetrapib/atorvastatin due to an increased rate of
mortality in patients receiving the combination
therapy [1]. The drug which has been in develop-
ment since the early 1990s was considered by Pfizer
as one of the most important new developments for
coronary heart disease (CHD) in decades. The de-
cision of the Data Safety Monitoring Board was
made after data analysis from the ILLUMINATE
study, a randomized, double-blind evaluation of the
effect of torcetrapib/atorvastatin vs atorvastatin
alone on the occurrence of major cardiovascular
events in 15 000 subjects with CHD or risk equiv-
alents. It was recommended that trial should be
halted due to an “imbalance of mortality and cardi-
ovascular events”. There were 82 deaths reported
in the group that received torcetrapib/atorvastatin
therapy and 51 deaths among those administered
atorvastatin [2]. This substantial increase of mor-
tality in patients receiving combination therapy was
the reason for not only stopping the trial but also
for suspending further research and production of
torcetrapib, bringing the company’s nearly 1 billion
dollars investment in the drug into a total loss.
The results of the ILLUSTRATE study evaluating
whether the combination of torcetrapib and ator-
vastatin provides greater benefit, in terms of reduc-
tion in progression of coronary disease as deter-
mined by coronary intravascular ultrasound assess-
ment of the atheroma volume, compared to
atorvastatin alone in patients with CHD will be pre-
sented at the Scientific Meeting of the American
College of Cardiology 2007 in New Orleans [2].
Several epidemiological studies have identified
both low-density lipoproteins (LDL) and high-den-
sity lipoproteins (HDL) as independent factors that
modulate the risk of coronary heart disease. Stat-
ins (HMG-CoA reductase inhibitors) which reduce
LDL levels and lower triglyceride levels are the
most commonly prescribed agents for the therapy
of hypercholesterolemia, and are considered the
most effective therapy in the prevention of athero-
sclerosis [3]. However, it has been shown that less
than 50% of treated patients respond favorably,
while the others continue to develop cardiovascu-
lar disease and in most of the non-responsive pa-
tients, low plasma HDL is encountered. Treatment
limited to LDL fails to capture a significant portion
of patients at risk for CHD, and patients effectively
treated for elevated LDL still experience a signifi-
cant number of coronary events.  Thus increasing
attention is being paid to other lipoprotein fractions,
such as HDL and triglycerides, as additional poten-
tial targets of therapy. Increased serum triglycer-
ides combined with low HDL, a condition often as-
sociated with smaller, dense LDL particles, is fre-
quently referred to as atherogenic dyslipidemia or
the „lipid triad” and is most often seen in the con-
text of the metabolic syndrome [3–6].
Epidemiological studies have demonstrated
that decreased HDL constitutes a powerful inde-
pendent risk factor for CHD and more importantly,
elevating HDL has been shown to decrease this risk
[7, 8]. Rising HDL levels is an important target for
treatment of dyslipidemia, especially in preexisting
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atherosclerosis, largely due to its function in re-
verse cholesterol transport. In addition, other im-
portant roles include fibrinolysis, antioxidant func-
tions, and the reduction of platelet aggregability.
Elevating HDL can be achieved by lifestyle chang-
es as well as by the use of statins, fibrates or nic-
otinic acid, albeit to a limited extent [9, 10]. Stat-
ins increase plasma HDL concentrations by 10%
to 15%, while fibrates and niacin raise HDL by up
to 25% to 30% [3, 10].
Several new therapies for substantially in-
creasing HDL cholesterol levels are under inves-
tigation. Recently published reviews by Kastelein
[8] and Forrester and Shah [11] describe different
potential methods of increasing HDL and/or en-
hancing reverse cholesterol transport, including
inhibitors of the cholesterol ester-transfer protein
(CETP), apolipoprotein A-I Milano, DF4 (synthetic
peptide mimetic of apolipoprotein A-I), the dual
peroxisome-proliferator-activated receptor ago-
nists, and rimonabant (an endocannabinoid recep-
tor inhibitor). Combining these new agents with
existing LDL cholesterol lowering agents may
improve the cardiovascular risk reductions cur-
rently attainable.
Extensive research conducted to develop novel
drugs to substantially increase HDL levels result-
ed in the development and clinical testing of CETP
inhibitors, a crucial protein in the transport of cho-
lesterol from the periphery to the liver for secre-
tion into bile, known as reverse cholesterol trans-
port [9, 11]. Two pharmacological small-molecule
inhibitors of CETP, JTT-705 (Roche) and torce-
trapib (Pfizer) have been shown to effectively raise
HDL cholesterol in humans when either used as
a monotherapy or combined with statins that lower
LDL cholesterol.
The CETP is a plasma glycoprotein manufac-
tured in the liver. It circulates in the blood, bound
predominantly to HDL. Two principal actions of
CETP have been identified. The primary action of
CETP is to mediate the transfer of cholesterol es-
ters from HDL to very low-density lipoproteins
(VLDL) and LDL in exchange for triglycerides.
CETP also promotes the transformation of HDL
2 to HDL 3, an action that could promote reverse
cholesterol transport. CETP inhibition, on the oth-
er hand, results in an increase in HDL by markedly
delaying catabolism of apolipoproteins apoA-I and
A-II. This action can also increase reverse choles-
terol transport. This overlap of the potential effects
of CETP and CETP inhibition has served to con-
found an understanding of potential therapeutic
mechanisms in atherosclerosis [11–13].
The CETP gene mutation discovered in the
Japanese population (with a prevalence of about
11%) was accompanied by a substantial increase in
HDL and affected individuals were resistant to
atherosclerosis [12–15]. During the ensuing years,
at least 13 different mutations in the coding region
of the CETP gene have been identified. Earlier stud-
ies in the Japanese population have demonstrated
that a CETP deficiency was associated with longev-
ity [12]. In a recent study on the lipoprotein pheno-
type and longevity, the subjects with exceptional
longevity (mean 98 years) were Ashkenazi Jews, as
well as their offspring [16]. There was a significant
increase in both HDL and LDL particle size in
probands and their offspring as compared to age
matched control groups. With regard to human
CETP mutations and the associated reduction in
CETP levels, recent analysis of prospective data is
consistent with the results of a previous study of
Japanese subjects in concluding that CETP deficien-
cy is protective when associated with HDL levels
≥ 60 mg/dl [14, 17]. A recent study with a seven-
year follow-up of 2340 men aged 71–93 in the Hono-
lulu Heart Program, demonstrated that the age-ad-
justed CHD incidence rates were significantly lower
in men with high versus low HDL levels [18]. Af-
ter adjustment for age, hypertension, smoking, and
total cholesterol, the relative risk of CHD for those
with HDL levels ≥ 60 mg/dl, compared to those
with HDL levels < 40 mg/dl, was 0.6. Men with
a CETP mutation had the lowest (although not sta-
tistically significant) rates of CHD. These data in-
dicate that HDL remains an important risk factor
for CHD in the elderly.
The first results from clinical trials on torce-
trapib were very promising and demonstrated its
ability to raise HDL levels very effectively. In
healthy young subjects with the highest torcetrapib
dose (120 mg/twice daily), CETP activity decreased
by 80%, while the CETP mass increased, apparently
because the mechanism of action of torcetrapib rep-
resents the shift of free CETP to the HDL-bound
form [19]. With the above treatment, plasma LDL
decreased by 42%, HDL increased by 91%, as did
apoA-I and apoE, by 27% and 66%, respectively,
while apoB was reduced by 26%. Cholesterol ester
content decreased and triglyceride content in-
creased in the non-HDL plasma fraction, with con-
trasting changes occurring in HDL. These effects
of CETP inhibition resembled those observed in
partial CETP deficiency.
In subjects with low HDL cholesterol levels,
CETP inhibition with torcetrapib markedly in-
creased HDL cholesterol levels and also decreased
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LDL cholesterol levels, both when administered as
monotherapy and when administered in combination
with atorvastatin [20]. Torcetrapib (120 mg/daily) has
been shown to increase HDL cholesterol levels by
46% when given alone and in combination with
atorvastatin (61%) as well as to decrease LDL cho-
lesterol levels by more than that achieved by ator-
vastatin alone. Treatment with torcetrapib (120 mg/
twice daily) increased HDL levels by 106%. Torce-
trapib also reduced LDL cholesterol levels by 17%
in the atorvastatin cohort.
A recent multi-center, randomized, double-
blind, placebo-controlled, parallel-group, dose-rang-
ing study on 493 subjects, evaluating torcetrapib and
atorvastatine for 12 weeks in patients with elevat-
ed LDL without overt CHD also demonstrated rapid
and dose-dependent increases in HDL and decreas-
es in LDL cholesterol [21]. In all published reports
no serious adverse events due to torcetrapib treat-
ment were reported. However, it has been demon-
strated that of the patients receiving torcetrapib,
1.6% experienced elevations in blood pressure defined
as 1) systolic blood pressure (SBP) ≥ 15 mm Hg or
diastolic blood pressure (DBP) ≥ 10 mm Hg from
baseline at 3 consecutive visits or 2) SBP ≥ 180 mm Hg
with a ≥ 20 mm Hg change from baseline or DBP
≥ 105 mm Hg with a ≥ 15 mm Hg change from base-
line at a single visit [22]. The mechanism behind
this response is unknown.
Data from the Lipid Research Clinics and the
Framingham Heart Study suggest that the total-to-
-HDL cholesterol ratio may be more predictive of
CHD than total cholesterol or LDL cholesterol [6, 23].
The current trend in dyslipidemia treatment is the
greater use of combination lipid altering drug therapy.
This tendency is largely due to the facts that:
1) atherosclerosis is a multifactorial process and its
treatment does not appear to be possible with a sin-
gle lipid altering drug that predominantly treats only
one lipid parameter; 2) more patients are being con-
sidered as candidates for more aggressive lipid
treatment goals, which cannot be achieved with one
lipid altering drug; 3) the use of two or more lipid
altering drugs in lower doses may result in less
potential for side effects and toxicity, while at the
same time have a greater potential for more global
improvement in lipid parameters by the use of dif-
fering lipid-altering agents that treat different lipid
targets [5].
Does the combined use of statins and CETP
inhibitors have the potential for markedly improv-
ing the effectiveness in reducing the risk of cardiac
events in patients with cardiovascular disease?  The
promising data on torcetrapib and atorvastatin dem-
onstrated the great expectations of this novel com-
bination therapy. However, the limited number of
clinical trials, investigating the pharmaceutical
CETP inhibition has shown an urgent need for large
randomized trials to judge the safety and efficacy
and to assess the long-term effects of CETP inhi-
bition on atherosclerosis. Considering the results
of today’s clinical practice of managing dyslipidemia,
another issue that warrants investigation is the safe-
ty and efficacy of combination therapy of CETP in-
hibition together with evidence-based LDL choles-
terol reduction. The extensive data on the short-
term and long-term effects of CETP inhibition in
humans will have to determine whether CETP in-
hibition decreases the risk of atherosclerotic dis-
ease in dyslipidemic patients.
In addition, recent data indicate that CETP in-
hibition may be beneficial to hypertriglyceridemic
individuals [4]; however, these results also need to
be confirmed by clinical endpoint trials. Despite
animal, epidemiological, and genetic data, we can-
not predict the antiatherogenic effect of CETP in-
hibition or identify populations in which the inter-
vention might be more or less effective. Although
CETP inhibitors have only been tested in a limited
number of patients and data from big multicenter
studies are not available yet, the current results
indicate that CETP inhibition has the potential to
be of great importance in the future treatment of
dyslipidemia.
The effect of CETP and its inhibition may be
modified by the genetic and metabolic milieu [11].
Based on human genetic data it has been speculat-
ed that CETP deficiency may be antiatherogenic
when it is associated with a significant increase in
HDL (> 60 mg/dL) but that it is not protective in
the presence of substantial hypertriglyceridemia
and major increases in LDL cholesterol. Studies in
hyperlipidemic rabbits are consistent with this idea
and suggest that despite a major increase in serum
HDL, the HDL itself is insufficient to be antiather-
ogenic. An additional reasonable speculation is that
the effect of the metabolic milieu on CETP inhibi-
tion may involve alterations in HDL function, ca-
tabolism, or particle distribution [11, 24].
Although there are several similar drugs to
torcetrapib in the pipeline, scientists are trying to
find out whether the problems with torcetrapib
come from lowering HDL cholesterol, lowering
a particular type of HDL cholesterol, or from some
unique characteristic of the torcetrapib molecule
itself. Researchers will likely investigate the con-
ditions related to hypertension, since the drug is
known to elevate blood pressure (3–4 mm Hg).
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Some experts believe the increase in blood
pressure could be managed, while others noted that
such an increase would translate, population wise,
into a 20% higher stroke mortality and a 12% high-
er mortality from CHD [2].
Studies on torcetrapib were undergoing criti-
cism already during development. When the first
human studies were launched, beside the strictly
scientific and clinical implications of torcetrapib tri-
als, there were also concerns about how Pfizer was
studying and marketing the future drug which was
hoped to be approved by the FDA in 2007. The com-
pany was planning to sell torcetrapib only in com-
bination with its own atorvastatin and Pfizer’s clin-
ical trials studied torcetrapib only in combination
with this best-selling drug in the world (sales of
atorvastatin account for about half of Pfizer’s annu-
al profits), on which the company’s patent is due to
expire in 2010. This controversial decision drew big
criticism from the medical community [25] and fi-
nally the company has changed its strategy. So far
there are almost no efficacy trial data based on the
combination therapy with the other statins.
The concept of HDL elevation is still intrigu-
ing and open for investigation. Several pharmaceu-
tical companies have similar compounds in the pipe-
line but after the recent experience with the torce-
trapib/atorvastatin combination, trials with HDL
elevating compounds will be under new scrutiny.
Most likely our understanding of HDL metabolism and
pathways is still incomplete and simple inhibition of
CETP may not be a solution. There is also a need
for pharmacogenomic investigations of the results of
the ILLUMINATE trial which could possibly unveil
which genetic polymorphism predispose to harmful
versus beneficial effect of the CETP inhibitors.
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